Metropolis Healthcare Q2 FY27: revenue up 15.8%, profit after tax up 42.7%
Q2 FY27 revenue up 15.8% to INR 496.8 Cr, EBITDA up 23.9% to INR 134.9 Cr, PAT up 42.7% to INR 75.5 Cr.
By ScoutQuest · · 1 min read
- Q2 FY27 Revenue
- INR 496.8 Cr, up 15.8% year on year
- Q2 FY27 EBITDA
- INR 134.9 Cr, up 23.9% (EBITDA margin 27.2%, up 180 bps)
- Q2 FY27 PAT
- INR 75.5 Cr, up 42.7% year on year
- Period
- Q2 FY27 (quarter ended Sep 30, 2026)
- Positioning
- A diagnostics chain whose laboratory and service network (213 labs, 5,119 service points at H1FY27) it says delivers volume-led growth, with Specialty at 40% and TruHealth at 17% of Q2 FY27 revenue.
📈 Q2 FY27 revenue rose 15.8% year on year to INR 496.8 Cr, reported EBITDA rose 23.9% to INR 134.9 Cr and profit after tax rose 42.7% to INR 75.5 Cr; EBITDA margin was 27.2%, up 180 bps. Patient volume was 4.07 Mn, up 10%, and test volume 8.68 Mn, up 11%.
🎯 For H1 FY27, revenue was INR 947.0 Cr, up 16.2%, with profit after tax up 34.9% to INR 132.4 Cr; the company says it delivered ahead of its growth guidance and that mid-teens growth came with no price hikes. Specialty contributed 40% of Q2 FY27 revenue and TruHealth 17%, both growing 20% year on year, per the presentation.
🏭 Management frames the plan as Metropolis 3.0: leading with technology and AI, differentiating scientifically, pursuing consistent profitable growth and a brand promise built on trust. It says scaling the core menu and genomics will speed specialty growth, and lists expansion into Oncology, Nephrology, Gynecology and infectious and chronic disease testing.
📈 Other income of INR 8.5 Cr in Q2 FY27, against INR 0.9 Cr a year earlier, contributed to the profit jump, and the company credits the 180 bps Q2 EBITDA margin gain to operating leverage, automation and productivity gains. It also reports a network now spanning ~750 towns, up from 300 in FY23.
Also from Metropolis Healthcare
Metropolis Healthcare Ltd press release, Q2 FY27
3 Nov 2026
Interim dividend of Rs. 1 per share declared; September quarter results approved
3 Nov 2026
Board approves results for quarter and half year ended September 30, 2026; declares interim dividend of INR 1 per share
3 Nov 2026
More numbers
- Revenue from operations, Q2FY27496.8 (Rs. Crs.)
- Reported EBITDA, Q2FY27134.9 (Rs. Crs.)
- Profit After Tax, Q2FY2775.5 (Rs. Crs.)
- Revenue from operations, H1FY27947.0 (Rs. Crs.)
- Profit After Tax, H1FY27132.4 (Rs. Crs.)
- Reported EBITDA margin, Q2FY2727.2%
- Other Income, Q2FY278.5 (Rs. Crs.)
- Patient volume, Q2FY274.07 Mn
- Test volume, Q2FY278.68 Mn
- Specialty share of revenue, Q2FY2740%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.